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1078–5Background. Nuclear medicine imaging differs from other imaging modalities by showing physiological processes instead
of anatomical details.
Objective. To describe the current applications of positron emission tomography (PET) and single photon emission
computed tomography (SPECT) as a diagnostic tool for vascular disease as relevant to vascular surgeons.
Methods. A literature search identified articles focussing on vascular disease and PET or SPECT using the Pubmed
database. Manual cross referencing was also performed.
Results. PET and SPECT may be used to assess plaque vulnerability, biology of aneurysm progression, prosthetic graft
infection, and vasculitis. The ability to combine computerized tomography scanning or magnetic resonance imaging
with PET or SPECT adds detailed anatomical information and enhances the potential of nuclear medicine imaging in
the investigation of vascular disease.
Discussion. Considerable further information will be needed to define whether and where PET or SPECT will fit in
a clinical strategy. The necessary validation studies represent an exciting challenge for the future but also may require
the development of interdisciplinary imaging groups to integrate expertise and optimize nuclear diagnostic potential.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Prosthesis infection.Introduction
Conventional imaging of atherosclerosis is based on
detecting the degree of luminal stenosis, which may
not be the best indicator of lesion activity or of clinical
risk.1 Similar maximum aneurysm diameter may not
be the only factor important in determining clinical
outcome.2 For example not all patients with a carotid
stenosis greater than 70% develop strokes, nor do all
aortic aneurysm > 6 cm rupture. Alternative imaging
strategies, such as positron emission tomography
(PET) and single photon emission computed tomogra-
phy (SPECT), may improve prediction of clinicalsponding author. C. J. Zeebregts, MD, PhD, Department of
y, Division of Vascular Surgery, University Medical Center
gen, P.O. Box 30 001, 9700 RB Groningen, The Netherlands.
address: czeebregts@hotmail.com
884/000507 + 07 $34.00/0  2007 European Society for Vasculaevents. In this manuscript the current applications of
PET and SPECT, as a diagnostic tool for both central
and peripheral vascular disease are discussed.Basic Principles
Nuclear imaging differs from many other imaging
modalities by focusing on physiologic processes in-
stead of anatomy. Images obtained by nuclear medi-
cine can be combined with those from other imaging
modalities, such as computer tomography (CT), to
highlight locations of interest. PET involves imaging
based on the detection of gamma radiation from the
emission of positrons. Radionuclides used in PET
scanning are typically isotopes with short half lives
such as 11C (w20 min), 13N (~10 min), 15O (w2 min),
and 18F (w110 min). Due to their short half lives,
most radionuclides must be produced in a cyclotronr Surgery. Published by Elsevier Ltd. All rights reserved.
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ner in order to prevent extended delivery-times to the
PET scanner. These radionuclides are incorporated
into compounds normally used by the human body
such as glucose, fatty acids, or antibodies and then
injected as radiopharmaceuticals to visualize active
processes. The acquired picture depends on several
important basic factors such as the resolution of the
detecting system e.g. the PET camera, the radiophar-
maceutical used and the degree of uptake in the target
organ or tissue.3 PET scanners have a spatial resolu-
tion of 2 mm at present and are mostly combined
with an incorporated CT system.
SPECT is similar to PET in detecting gamma radia-
tion. There are some differences between SPECT and
PET. The spatial resolution of SPECT is about 10 mm,
i.e. lower than PET, but SPECT can also be equipped
as a hybrid SPECT-CT system. Radioactive substances
typically used in SPECT include 99mTechnetium,
123Iodine, and 111mIndium. In general these radioactive
substances have longer decay times than those used in
PET and can also be labeled with pharmaceuticals.
Other differences include the higher costs of the PET
camera, the double headed camera in SPECT whereas
PET is based on a ring system, the absolute quantifica-
tion in PET compared to semi-quantification in SPECT,
and the need of a cyclotron for most PET radiopharma-
ceuticals. Most common uses of PETand SPECT to date
have been in the field of oncology (tumor detection,
staging, and monitoring treatment effect), assessment
of cardiac viability and left ventricular function.4,5
Interestingly, when performing whole body PET for
tumor imaging, increased uptake was observed in
large arteries.6 It was hypothesized that this increased
uptake in arteries was related to the severity of
atherosclerosis.Table 1. Targets for nuclear medicine imaging and the tracers that
can be used within the field of vascular disease







Matrix metalloproteinase 123I-HO-CGS 27023A
Angiogenesis 123I-VEGF165
Apoptosis 99mTc-annexin-V
FDG¼ fluorodeoxyglucose, MCP-1¼monocyte chemotactic
protein-1, Tc¼ technetium, I¼ Iodine, MDA¼malondialdehyde,
123I-HO-CGS 27023A¼MMP inhibitor, VEGF¼ vascular endothe-
lial growth factor.Imaging of Plaque Vulnerability
Plaque formation and vulnerability
Angiography is still regarded as the gold standard
for evaluation of progression in atherosclerotic dis-
ease.7 However, angiography does not always iden-
tify atherosclerotic plaques at risk of cap rupture.7
Atherosclerosis is a multifactor disease combining
metabolic burden, e.g. accumulation of oxidized
low-density lipoproteins (LDL), with inflammatory
reactions such as activation of chemotactic proteins
and monocytes recruitment.8e11 Apoptosis of macro-
phages and production of proteinases may lead to
plaque destabilisation and rupture. However, not
every lesion advances into a vulnerable plaque asEur J Vasc Endovasc Surg Vol 35, May 2008there is a delicate balance between degradation and
the stabilization response mediated by smooth mus-
cle cells.11e14
If PET and SPECT are to gain a position as a clinical
instrument in search of the vulnerable plaque, specific
tracers are needed to image components which play
an important role in the formation and progression
of vulnerable plaques. Table 1 lists several tracers
which can be used to image plaque vulnerability.
The most widely available tracer for analysis of pla-
que inflammation is FDG. FDG is a glucose analogue
that is taken up by glucose-using cells and phosphor-
ylated by hexokinase. However, no further intracellu-
lar metabolization takes place, which results in an
accumulation of the tracer intracellularly.15 FDG is
known to accumulate in inflammatory lesions, a key
feature of atherosclerosis. Other radiolabeled tracers
are available for imaging features of the vulnerable
plaque, such as oxidized LDL accumulation and apo-
ptosis (Table 1).16e22
Detection of plaque vulnerability
The indication for intervention in patients with internal
carotid artery stenosis is currently determined by the
duplex ultrasound grade of the stenosis in most cen-
ters. However, plaque vulnerability and risk of rupture
is usually a consequence of inflammatory reactions
within the plaque. Imaging of plaque inflammation
by PET/SPECT may add important diagnostic infor-
mation for both tailoring and monitoring treatment.
Davies et al. showed in their pilot study that carotid
plaques can be imaged with FDG-PET in patients
with carotid stenosis. Interestingly, symptomatic pla-
ques accumulate more FDG compared to asymptom-
atic lesions.23 The estimated net FDG accumulation
rate (plaque/integral plasma) in symptomatic lesions
509PET/SPECT Imaging in Vascular Diseasewas 27% higher than in contralateral asymptomatic
lesions. There was no measurable FDG uptake in
normal carotid arteries. Autoradiography of excised
plaques confirmed accumulation of deoxyglucose in
macrophage-rich areas of the plaque. In an effort to
link FDG PET to vulnerable plaques, Arauz et al. per-
formed PETanalyses on patients with recent symptom-
atic carotid lesions.24 They found strong FDG uptake in
11 out of 13 symptomatic patients. Despite treatment, 6
patients suffered from a stroke, death or re-stenosis,
during follow-up. All of these 6 patients had strong
FDG uptake. However, the small group size and di-
verse treatment options make it impossible to draw
any real conclusion.
SPECT analysis of radiolabeled cytokines may
further image plaque inflammation. For instance,
99mTc-IL2 targets high-affinity interleukin 2 receptors,
and, thereby, could be an useful monitor of carotid
plaques inflammation and vulnerability.20,25 The accu-
mulation of 99mTc-IL2 in carotid plaques is correlated
with the amount of IL2Rþ cells and is influenced by
lipid-lowering treatment with statins.
Metabolic stress is another important aspect of
plaque formation and vulnerability. Radiolabeled
(oxidized) LDL may be used to study in vivo distri-
bution and metabolism of native LDL. Lees et al.
found focal accumulation in vivo of 99mtechnetium
(Tc) labelled LDL in four out of 17 patients with
atherosclerotic disease using a gamma scintillation
camera.26 The carotid specimens that had shown
accumulation of 99mtechnetium on SPECT analyses,
were found to have high levels of foam cells and mac-
rophages and poorly organized intramural blood con-
sistent with plaque haemorrhage. In contrast, lesions
which weren’t visible on SPECT analysis were found
to be mature and fibrocalcified plaques on histological
examination. Iuliano et al. developed a technique to
oxidize autologous LDL and analyzed its biodistribu-
tion in relation to carotid stenosis.27 The authors
found that the uptake of 99mTc-oxLDL by carotid pla-
ques was significantly higher compared to that in nor-
mal carotid arteries ( p< 0.02). Uptake of 99mTc-oxLDL
above that measured in normal carotid arteries was
observed in 10 out of 11 patients with symptomatic
carotid stenosis (91%, confidence interval 58.7 to
99.8). There was no correlation between the degree
of stenosis and degree of 99mTc-oxLDL uptake in the
plaque lesion.27,28
Clinical data on the imaging of plaque vulne-
rability at other sites is limited. Most studies
describe the use radiolabeled tracers in animal
experiments comparing imaging results with histo-
pathological analyses of macrophages burden and
apoptosis.17,19,29,30Imaging of Aneurysms
The risk of rupture of aneurysms such as abdominal
aortic aneurysm (AAA) increases with the diameter
of the aneurysm. However, rupture also occurs in
small AAAs, and it would therefore be useful to de-
fine predictors of accelerated growth or increased rup-
ture risk. The risk of rupture may be related to the
level of MMP activation in the smooth muscle cells
of the aneurysm wall. Sakalihasan et al. showed a pos-
sible association between increased FDG uptake and
AAA expansion and rupture.31e33 In their prospective
study 10 out of 26 patients with an AAA had in-
creased FDG uptake. Ninety percent of them required
urgent surgery within 30 days for rupture or symp-
tomatic complications. In those without increased
FDG uptake, none needed urgent surgery.
Recently, thrombus in the AAA was found to be
biologically active and involved in permanent platelet
activation and apoptosis.34,35 Annexin V specifically
binds with high affinity to PS, which is exposed to
the surface of apoptotic cells and activated platelets.
99mTc-annexin-V has previously been used for in vivo
scintigraphy of apoptotic cells both in animals and
humans.29 Sarda-Mantel et al. showed that 99mTc-
annexin-V activity was located in the thrombus area
where activated platelets and leukocytes accumu-
lated.36,37 Similar patterns were also found in all of
the human AAA thrombi harvested during surgery.
99mTc-annexin-V imaging may assess mural thrombus
renewal activity.Imaging of Graft Infection
Vascular prosthesis infection is a serious complication
with high morbidity and mortality.38 Vascular graft in-
fections are usually detected by CT or MRI, but there
is growing interest in PET as a modality for imaging
infection. Increased FDG uptake may be seen in areas
of activated granulocytes. Fig. 1 shows the fused
PET/CT images in a patient with an infected aorto-
iliac prosthetic graft. Previous studies demonstrated
the value of PET in analyzing suspected aortic graft
infections.39 FDG-PET was performed in a study of
33 consecutive patients with a suspected arterial
prosthetic graft infection. Based upon surgical, micro-
biological, and clinical follow-up, 11 patients were
considered to have a graft infection. PET had a sensi-
tivity of 91% and specificity of 95%, which was higher
than CT findings. Importantly, previous studies have
also shown false-positive accumulation of FDG dur-
ing vascular prosthetic graft replacement. This false-
positive accumulation may be related to the reactionEur J Vasc Endovasc Surg Vol 35, May 2008
Fig. 1. Fifty-eight-year-old male patient, who suffered Q-fever (Coxiella burnetii) causing an infected aorto-iliac Dacron
prosthesis, which had been inserted seven months before during exclusion of an inflammatory abdominal aortic aneurysm
(A. CT image, B. PET image, and C. Fused PET-CT).
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flammation. Many others have reported case series
of PET scanning in patients with graft infection and
aorta-enteric fistula.38,40,41
Interestingly, mild increased FDG uptake in cardio-
vascular prosthesis years after surgery is not always
related to infection. Duet et al. recently presented
a case with a high level of FDG uptake over a prosthe-
sis a few days before the occurrence of an acute graft-
related thrombosis.42 The patient had undergone
vascular prosthetic surgery 5.5 years previously. In
their opinion the intense uptake could no longer be
related to the postoperative development of a pseu-
dointima, a physiologic process due to inflammation
and cell colonization occurring within the graft. In
their report, infection was ruled out by bacteriologic
graft analysis. Therefore, they suggested that, some
time after bypass surgery, FDG uptake over a vascular
prosthesis seen on PET/CT could also suggest lesions
at risk of future acute cardiovascular events.Fig. 2. PET/CT fused images of a 57-year-old male patient
with giant-cell arteritis, showing vasculitis of the greater
vessels, with extensive 18F-FDG at the level of the carotids,
subclavian arteries, thoracic and abdominal aorta, and in
both femoral arteries (from left to right: transverse, sagittal
and coronal view, respectively).Imaging of Vasculitis and Aortitis
Vasculitis and mycotic aneurysms are examples of
other vascular challenges where PET may aid in the as-
sessment. In 1999, the first use of PET in vasculitis was
reported.43 Fig. 2 shows the PET/CT fused images of
a patient with giant-cell arteritis. The increased FDG
uptake analyzed by PET, seems to be a specific finding
in vasculitis such as giant cell arteritis.44e47 The tem-
poral arteries cannot be visualized due to their small
diameters and superficial localization. BlockmansEur J Vasc Endovasc Surg Vol 35, May 2008et al. showed in a study of 69 patients with vasculitis
(giant cell arteritis, polymyalgia rheumatica) and 44
controls (temporal artery biopsies) an increased up-
take of FDG in patients with vasculitis.48 Thoracic
vascular uptake of FDG had a positive predictive
value of 93% and a negative predictive value of 80%.
FDG PET has the advantage of identifying all sites of
inflammation within one scan. Several case reports
511PET/SPECT Imaging in Vascular Diseaseand small case series have been published that confirm
the initial findings of FDG uptake in vasculitis.49e51
However, it is important to realize that other vascular
diseases such as arteriosclerosis might produce false-
positive results. Yun et al. analyzed the presence of
FDG uptake in 137 patients who underwent PET pre-
dominantly for malignant diseases.6 More than 50%
showed increased uptake in one or more large vessels.
On the other hand, increased uptake in vessels not
prone to atherosclerosis, such as the subclavian artery,
increases the specificity for true vasculitis. De Leeuw
et al. showed the therapeutic effect of corticosteroids
on vasculitis. Vasculitis activity disappeared on FDG
PET after steroid treatment.52
Mycotic aneurysms are a rare entity, but may pose
a challenging problem in diagnosing.53 Survival is
markedly increased by prompt diagnosis and surgical
treatment. In early reports, most infected aneurysms
were related to valvular infection, however nowadays
most mycotic aneurysms are aortitis related.54 Bacte-
rial seeding of the aortic wall can occur by hematoge-
nous spread, lymphatic spread or direct extension
from an adjacent infected focus.55e57 The intimal lin-
ing of the aorta is generally highly resistant to infec-
tion. However, even normal aortic intima can be
subject to bacterial invasion. Secondary degeneration
of the arterial wall may result in aneurysm formation
and rupture. Rupture may occur as early as one week
after the onset of aortitis.57 In the absence of the clas-
sical signs (fever, pulsatile mass, positive blood cul-
ture), the diagnosis of mycotic aneurysm is difficult.
A CT scan might provide an early diagnosis, showing
irregular peripheral enhancement of the aneurysm
wall.58 Davison recently presented a case where the
diagnosis was confirmed by different imaging modal-
ities, including FDG PET.59 Combined PET/CT dem-
onstrated increased FDG metabolism within the wall
of the aneurysm. Others have shown comparable
results for FDG PET and aneurysms, and PET/CT
may be a new addition to the work-up for suspected
mycotic aneurysm due to aortitis.60Conclusion
The ability to non-invasively image physiological and
biochemical processes opens clinically relevant diag-
nostic applications and fascinating possibilities for
basic scientific research. Imaging of plaque vulnera-
bility, graft infection and vasculitis by nuclear
medicine techniques may add in diagnosis and man-
agement. Further information will be needed to de-
fine whether and where PET or SPECT will fit in
a clinical strategy. Especially, the predictive valuefor vascular events has to be substantiated. The in-
creasing infrastructure of hybrid PET-CT or SPECT-
CT scanners and new tracers has set the stage for
more widespread use. Optimal radioactive tracers
are needed, with high sensitivity, specificity and
high background to target ratio. Importantly, cost,
product availability, reimbursement, and patient re-
ferral will be important factors defining future use
of nuclear imaging in vascular disease. The necessary
validation studies represent an exciting challenge for
the future but also may require the development of
interdisciplinary imaging groups to integrate exper-
tise and optimize nuclear diagnostic potential.References
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